The Latest “Buzz on the Street” Show: Featuring Pasha Brands (CSE: CRFT) (OTC: CRFTF) North 40 Cannabis Agreement

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pasha Brands Secures Supply Agreement with Canada’s First Licensed Micro Processor, North 40 Cannabis.”

Pasha Brands Ltd. (CSE: CRFT) (OTC: CRFTF) (FSE: ZZD), North America’s largest craft cannabis brand house, is pleased to announce that its wholly owned subsidiary, BC Craft Supply Co. Ltd (“BC Craft”), has signed a supply agreement with Canada’s first licensed micro processor, North 40 Cannabis.

Based in Vancouver, British Columbia, Pasha Brands is a vertically integrated organization that is firmly rooted in BC’s craft cannabis industry, which boasts an international reputation. With proven capabilities in cannabis cultivation, genetic research and development, product, processing, and retail, Pasha is uniquely positioned in the new legal cannabis market through its network of hundreds of craft cannabis suppliers under the Pasha umbrella.

Pasha’s subsidiary, BC Craft Supply Co. Ltd., is developing a craft cannabis campus, which is dedicated to bringing craft quality into the newly legal cannabis market in Canada. BC Craft Supply Co. Ltd. is driven to assist craft growers in obtaining security clearance and licensing to grow as micro-cultivators, specializing in education and compliance to bring growers into the regulated cannabis supply market.

As the cannabis industry continues to evolve, researchers are constantly uncovering new aspects of the plants. For instance, a study by the University of Colorado suggested that cannabis can be used to increase the survivability of a heart attack. The study collected over 1.2 million medical records of acute myocardial infarctions (AMI) and among those records, it was discovered that 3,854 of those patients were cannabis consumers. While it would be likely assumed that they would have more adverse conditions than non-consumers, it was the exact opposite, as the researchers noted that the cannabis consumers had a decreased risk of death, shock, or need to insert a balloon into a blocked artery. The researchers mentioned that they do not exactly understand the scientific reasoning behind increased survivability. However, they speculated that the activation of CB2 receptors found in the endocannabinoid system can provide therapeutic cardioprotective effects. The researchers then pointed to another study that suggested cannabis could increase blood flow, preventing blood clots and strokes. Furthermore, a multitude of studies have also concluded that cannabis can be effectively used to treat other medical conditions such as symptoms associated with cancer, chronic pain, epilepsy, and multiple sclerosis. Medical cannabis is predominantly used among patients suffering from chronic pain because the activation of the CB2 receptors can help alleviate the pain as well as reduce inflammation. Moreover, thousands of medical institutions and researchers are conducting trials to better understand the psychological and neurological effects of cannabis. And while the industry remains within its infancy stage, it is rapidly accelerating. In the near future, cannabis could potentially become a globally available medicinal treatment for a variety of conditions. As a result, the global legal marijuana market is expected to reach USD 146.4 Billion by 2025 while registering a CAGR of 34.6%, according to data compiled by Grand View Research. 

Medical cannabis is already prevalent in many regions across the world such as parts of the U.S., AustraliaCanadaFranceGermanyThailand, and South Korea. However, due to the lack of research and the plant’s potential for abuse, government regulators have explicitly outlined the requirements patients must meet in order to be eligible for medical use. Germany’s parliament allows patients to use medical cannabis for multiple sclerosis and chronic pain, but it heavily depends on the severity of their condition. On the other hand, South Korea only allows the use of medical cannabis for epilepsy, symptoms of HIV/AIDS, and cancer-related treatments. While Germany and South Korea recently adopted medical cannabis, the U.S. and Canada have had medical cannabis use for quite some time. The U.S. began adopting medical cannabis back in the 1990s when California became the first state to legalize medical use. Canada legalized medical cannabis use back in 2001, but only allowed it for two uses. Since then, both markets have drastically changed and additionally, both have implemented a recreational market. Largely, the U.S. and Canada dominate cannabis market because of their early adoption. However, the major challenge for companies is keeping up with trends. For instance, when legalization first began, dried cannabis flower was widely popular. Now ,however, oils are in high demand. Moreover, consumer preferences have changed and consumers are beginning to demand more premium and higher quality products. Specifically, in the U.S. and Canada, “craft cannabis” has become an emerging product that is quickly gaining popularity. Cultivators engaging in craft cannabis carefully nurture each individual plant to ensure its high quality and potency. Notably, craft cultivators also grow their cannabis organically, meaning they avoid the use of artificial products that may damage the strain and cannabinoid content. Overall, the meticulous care and distinct growing techniques create an eccentric strain that stands out from traditional products. “More and more consumers desire a tangible connection with the cannabis flower and care about small farm values such as sustainability, craftsmanship, organic principles and hands-on cultivation techniques,” said Rose Mattio, Founder of Rosie Mattio Public Relations.

For more information, please visit: Pasha Brands Ltd.

For more corporate news on Pasha Brands Ltd., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

3 Comments
  1. Walt Newman 2 months ago
    Reply

    having more domestically grown cannabis is great as the costs will be much cheaper than continually purchasing from international brands that are shipped in.

  2. Phil Wahba 2 months ago
    Reply

    the cannabis sector is having a rough time at the moment, could be a good time to get a starter

  3. Vanessa Louie 2 months ago
    Reply

    “According to Health Canada, as of July 31, there were 192 applications” for micro #cannabis cultivation licences
    Only very few have been approved.

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pasha brands ltd. financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.